By Eyewire News
The podcast currently has 16 episodes available.
The CEO of Lumithera joins us to discuss the FDA authorization of the Veleda system for dry AMD; the FDA accepts the resubmitted NDA for dry eye disease candidate reproxalap; and Alcon launches the first contact lens designed for a 1-week replacement cycle.
Learn more about your ad choices. Visit megaphone.fm/adchoices
Leaders of several ophthalmic companies with a focus on the posterior segment provide updates on their pipeline and new products in this special edition of EyewireTV.
Learn more about your ad choices. Visit megaphone.fm/adchoices
We hear from executives representing pharma and device manufacturers in the anterior segment who provide updates on their companies’ recently launched products and those in development.
Learn more about your ad choices. Visit megaphone.fm/adchoices
Several companies with product candidates in the posterior segment provide updates; Ocuphire acquires an ophthalmic gene therapy company; and Astellas provides an update on its regulatory plans for GA drug avacincaptad pegol.
Learn more about your ad choices. Visit megaphone.fm/adchoices
Eyewire News: The Podcast reports on new products and breaking news live from the American Academy of Ophthalmology meeting in Chicago.
Learn more about your ad choices. Visit megaphone.fm/adchoices
Bausch + Lomb receives FDA approval for a new IOL on its enVista platform; Nanoscope advances it gene therapy for retinitis pigmentosa; and Orasis completes a major funding round to support the launch of its presbyopia eye drop.
Learn more about your ad choices. Visit megaphone.fm/adchoices
Aldeyra resubmits its NDA for dry eye drug reproxalap; Clearside announces new phase 2b topline data for its investigational extended-release wet AMD drug; and Bausch + Lomb launches a new digital e-commerce marketplace.
Learn more about your ad choices. Visit megaphone.fm/adchoices
Novaliq’s water-free ciclosporin-based eye drop for dry eye disease is approved in Europe; the FDA approves first new ophthalmic steroid in over 15 years; and the first slit-lamp mounted rebound tonometer is launched in the US and Europe.
Learn more about your ad choices. Visit megaphone.fm/adchoices
Two collaborations are made to develop and market new glaucoma treatments; Apellis receives feedback from a committee of thee EMA for its geographic atrophy treatment pegcetacoplan; and Topcon receives FDA clearance for OCTA on the company’s Maestro2 fundus camera system.
Learn more about your ad choices. Visit megaphone.fm/adchoices
EyewireTV reports on new products and breaking news live from the European Society of Cataract and Refractive Surgeons Congress in Barcelona.
Learn more about your ad choices. Visit megaphone.fm/adchoices
The podcast currently has 16 episodes available.